Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: A single-centre study of 163 patients
Systemic therapy
DOI:
10.1016/j.ejso.2014.07.043
Publication Date:
2014-09-28T13:02:49Z
AUTHORS (8)
ABSTRACT
Patients with muscle-invasive bladder cancer (MIBC) often undergo various preoperative treatments to improve survival; however, their efficacy and safety remain unclear.The anti-tumour effects adverse events were evaluated in 163 MIBC patients who received systemic chemotherapy (SC, n = 34), intra-arterial (IAC, 50), or combined IAC radiotherapy (IAC + R, 79).Pathological complete responses observed 17.6%, 22.0%, 43.0% of the SC, IAC, R groups, respectively, respective 5-year overall survival rates 42.0%, 46.7%, 50.3%. Multivariate analysis showed that successful protocol administration was a significant predictor for (hazard ratio 0.16, p 0.028). The incidence severe higher group (36.7%) than SC (9.8%) groups (16.0%).IAC useful MIBC. Successful completion optimal patient selection important this treatment strategy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (22)
CITATIONS (15)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....